CD274 and cancer: As a TME component in RCC, although the PD-L1 expression is recognized as a predicted marker for response to immune checkpoint inhibitors (ICIs) in several cancers such as non-small cell lung carcinoma [48], it has not proven to be a relevant predictive biomarker in metastasis ccRCC.